Alzheimer's & Dementia: The Journal of the Alzheimer's Association RSS feed: Articles in Press. The mission of Alzheimer's & Dementia: Journal of the Alzheimer's Association is to bridge the knowledge gaps across a wide range of bench-to-bedside investigation. The journal publishes the results of studies in: behavior, biochemistry, genetics, molecular biology, pharmacology, physiology, protein chemistry, neurology, neuropathology, psychiatry, geriatrics, neuropsychology, epidemiology, sociology, health services research, health economics, political science and public policy. Content emphasizes interdisciplinary investigations, integrative/translational articles, related to: etiology, risk factors, early detection, disease modifying interventions, prevention of dementia and applications of new technologies in health services. The journal publishes • comprehensive reviews; • research articles; • information on clinical trials; • short reports; • in-depth perspectives/open-peer commentaries; • theoretical and/or translational papers that attempt integrate knowledge across discipline; • history & politics of science/brief biographies and, • abstracts of papers presented at international meetings. Negative results, particularly clinical trials, are published as short communications. The ultimate objective is to create a novel forum for: • rapid communication of new findings, ideas or perspectives; • disseminating knowledge, across the spectrum of basic to clinical studies, necessary for optimal translation of research findings into practical applications/interventions; • integrating knowledge across disciplines; • increase knowledge in diverse disciplines to promote early detection/diagnosis and/or interventions; • formulating new theories and/or strategies for the rigorous testing of theories or their predictions; • identifying promising new directions of research and, • providing the scientific impetus for new initiatives; or public policies concerning research on prevention and new models of health services. Alzheimer's & Dementia is indexed/abstracted in Index Medicus/MEDLINE, Scopus, Science Citation Index Expanded (SciSearch®), Current Contents®/Clinical Medicine, Neuroscience Citation Index®, and Journal Citation Reports/Science Edition.http://www.alzheimersanddementia.com//inpress?rss=yesElsevier Inc.en © 2010 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved. Alzheimer's & Dementia: The Journal of the Alzheimer's Association1552-52602010-09-02 © 2010 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved. healthpermissions@elsevier.comhttp://www.alzheimersanddementia.com/article/PIIS1552526010001032/abstract?rss=yesAbstract: Background: A mathematical model was developed to describe the longitudinal response in Alzheimer's Disease Assessment Scale-cognitive (ADAS-cog) obtained from the Alzheimer's Disease Neuroimaging Initiative.Methods: The model was fit to the longitudinal ADAS-cog scores from 817 patients. Risk factors (age, apolipoprotein ɛ4 [APOE ɛ4] genotype, gender, family history of AD, years of education) and baseline severity were tested as covariates.Results: Rate of disease progression increased with baseline severity. Age, APOE ɛ4 genotype, and gender were identified as potential covariates influencing disease progression. The rate of disease progression in patients with mild to moderate AD was estimated as approximately 5.5 points/yr.Conclusions: A disease progression model adequately described the natural decline of ADAS-cog observed in Alzheimer's Disease Neuroimaging Initiative. Baseline severity is an important covariate to predict a curvilinear rate of disease progression in normal elderly, mild cognitive impairment, and AD patients. Age, APOE ɛ4 genotype, and gender also influence the rate of disease progression.Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database - Corrected ProofKaori Ito, Brian Corrigan, Qinying Zhao, Jonathan French, Raymond Miller, Holly Soares, Elyse Katz, Timothy Nicholas, Bill Billing, Richard Anziano, Terence Fullerton, the Alzheimer's Disease Neuroimaging Initiative10.1016/j.jalz.2010.03.018Alzheimer's & Dementia: The Journal of the Alzheimer's Association (2010)2010-09-02Alzheimer's & Dementia: The Journal of the Alzheimer's Association2010-09-02RESEARCH ARTICLEhttp://www.alzheimersanddementia.com/article/PIIS1552526010000403/abstract?rss=yesAbstract: Background: Docosahexaenoic acid (DHA) plays an important role in neural function. Decreases in plasma DHA are associated with cognitive decline in healthy elderly adults and in patients with Alzheimer's disease. Higher DHA intake is inversely correlated with relative risk of Alzheimer's disease. The potential benefits of DHA supplementation in age-related cognitive decline (ARCD) have not been fully examined.Objective: Determine effects of DHA administration on improving cognitive functions in healthy older adults with ARCD.Methods: Randomized, double-blind, placebo-controlled, clinical study was conducted at 19 U.S. clinical sites. A total of 485 healthy subjects, aged ≥55 with Mini-Mental State Examination >26 and a Logical Memory (Wechsler Memory Scale III) baseline score ≥1 standard deviation below younger adults, were randomly assigned to 900 mg/d of DHA orally or matching placebo for 24 weeks. The primary outcome was the CANTAB Paired Associate Learning (PAL), a visuospatial learning and episodic memory test.Results: Intention-to-treat analysis demonstrated significantly fewer PAL six pattern errors with DHA versus placebo at 24 weeks (difference score, −1.63 ± 0.76 [−3.1, −0.14, 95% CI], P = .03). DHA supplementation was also associated with improved immediate and delayed Verbal Recognition Memory scores (P < .02), but not working memory or executive function tests. Plasma DHA levels doubled and correlated with improved PAL scores (P < .02) in the DHA group. DHA was well tolerated with no reported treatment-related serious adverse events.Conclusions: Twenty-four week supplementation with 900 mg/d DHA improved learning and memory function in ARCD and is a beneficial supplement that supports cognitive health with aging.Trial Registration: Clinicaltrials.gov, Identifier: NCT0027813.Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline - Corrected ProofKarin Yurko-Mauro, Deanna McCarthy, Dror Rom, Edward B. Nelson, Alan S. Ryan, Andrew Blackwell, Norman Salem, Mary Stedman, on behalf of the MIDAS Investigators10.1016/j.jalz.2010.01.013Alzheimer's & Dementia: The Journal of the Alzheimer's Association (2010)2010-05-03Alzheimer's & Dementia: The Journal of the Alzheimer's Association2010-05-03RESEARCH ARTICLES